​Discovery Research: From Microbial Metabolites to Metabolic Restoration

Our lead compound, 4-cresol, was discovered through global academic collaborations and shows a novel mechanism of action. Peer-reviewed studies in Cell Reports (2020)[1] and PLoS One (2024)[2] confirm: 

​

• Enhances insulin secretion in response to glucose, supporting glycemic control

→ Helps the body regulate blood sugar on its own — not just with meds

​

• Reduces adiposity in both lean and obese preclinical models, indicating systemic metabolic improvement

→ Suggests a deeper fix — not just weight loss or appetite control

​

• Stimulates β-cell proliferation and islet neogenesis, targeting the core dysfunction of type 2 diabetes

→ Rebuilds the cells that actually make insulin — a novel approach compared to current treatments

​

• Demonstrates a favorable safety profile, with no off-target effects across 241 GPCRs and 468 kinases

→ Clean safety in early models = better odds of success in clinic

​​​

 

• Obesity Focus: In preclinical models, 4-cresol reduced adiposity in both lean and obese animals—a rare phenotype that suggests deep metabolic reprogramming, not appetite suppression
   → This supports its potential as a next-generation obesity therapy that restores systemic energy balance
  ​

• NAFLD/NASH Potential: Systemic improvements in insulin sensitivity and adiposity reduction point to potential benefits in nonalcoholic fatty liver disease (NAFLD) and NASH.

 → Our regenerative approach offers a distinct entry point into this market, which lacks disease-modifying oral therapies.

​

Our discovery efforts are supported by:

• Next-generation sequencing (NGS) to map microbiome-linked metabolic signals

• Machine learning to identify tractable pathways and prioritize compounds

• Validated preclinical models of diabetes, obesity, and liver disease

 

This is a new class of therapy: regenerative, targeted, and rooted in human biology backed by peer-reviewed science, we’re turning microbiome insights into real-world therapeutics.

For patients, it promises longer-lasting outcomes with fewer side effects.
For investors, it signals a scalable platform, a global market opportunity, and a chance to help lead a category-defining shift in metabolic care.

 

[1] Brial F, Alzaid F, Sonomura K, Kamatani Y, Meneyrol K, Le Lay A, Péan N, Hedjazi L, Sato TA, Venteclef N, Magnan C, Lathrop M, Dumas ME, Matsuda F, Zalloua P, Gauguier D. The Natural Metabolite 4-Cresol Improves Glucose Homeostasis and Enhances β-Cell Function. Cell Rep. 2020 Feb 18;30(7):2306-2320.e5. doi: 10.1016/j.celrep.2020.01.066. PMID: 32075738.  https://www.sciencedirect.com/science/article/pii/S2211124720300917?via%3Dihub

[2] Brial F, Puel G, Gonzalez L, Russick J, Auld D, Lathrop M, Poirier R, Matsuda F, Gauguier D. Stimulation of insulin secretion induced by low 4-cresol dose involves the RPS6KA3 signalling pathway. PLoS One. 2024 Oct 24;19(10):e0310370. doi: 10.1371/journal.pone.0310370. PMID: 39446839; PMCID: PMC11500888.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0310370